Trial · NCT00049517
Adverse events264
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 264
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Standard Daunorubicin (Induction Therapy) | 319 | 328 | |
| other | Anemia | Blood and lymphatic system disorders | High Dose Daunorubicin (Induction Therapy) | 318 | 325 | |
| other | Leukopenia | Blood and lymphatic system disorders | Standard Daunorubicin (Induction Therapy) | 281 | 328 | |
| other | Leukopenia | Blood and lymphatic system disorders | High Dose Daunorubicin (Induction Therapy) | 267 | 325 | |
| other | Neutropenia | Blood and lymphatic system disorders | Standard Daunorubicin (Induction Therapy) | 243 | 328 | |
| other | Neutropenia | Blood and lymphatic system disorders | High Dose Daunorubicin (Induction Therapy) | 230 | 325 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Standard Daunorubicin (Induction Therapy) | 295 | 328 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | High Dose Daunorubicin (Induction Therapy) | 292 | 325 | |
| other | Nausea | General disorders | Standard Daunorubicin (Induction Therapy) | 16 | 328 | |
| other | Nausea | General disorders | High Dose Daunorubicin (Induction Therapy) | 18 | 325 | |
| other | Fatigue | General disorders | Standard Daunorubicin (Induction Therapy) | 11 | 328 | |
| other | Fatigue | General disorders | High Dose Daunorubicin (Induction Therapy) | 18 | 325 | |
| serious | Bone Marrow Cellularity | Musculoskeletal and connective tissue disorders | Standard Daunorubicin (Induction Therapy) | 0 | 328 | |
| serious | Bone Marrow Cellularity | Musculoskeletal and connective tissue disorders | High Dose Daunorubicin (Induction Therapy) | 1 | 325 | |
| serious | Anemia | Blood and lymphatic system disorders | Standard Daunorubicin (Induction Therapy) | 257 | 328 | |
| serious | Anemia | Blood and lymphatic system disorders | High Dose Daunorubicin (Induction Therapy) | 251 | 325 | |
| serious | Hemolysis | Blood and lymphatic system disorders | Standard Daunorubicin (Induction Therapy) | 1 | 328 | |
| serious | Hemolysis | Blood and lymphatic system disorders | High Dose Daunorubicin (Induction Therapy) | 0 | 325 | |
| serious | Leukopenia | Blood and lymphatic system disorders | Standard Daunorubicin (Induction Therapy) | 320 | 328 | |
| serious | Leukopenia | Blood and lymphatic system disorders | High Dose Daunorubicin (Induction Therapy) | 323 | 325 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00049517/events